John Rother is president and CEO of the National Coalition on Health Care
The most recent example of pharmaceutical price gouging in the United States to catch public attention involves the EpiPen (adrenaline/epinephrine), a widely used injectable pen that can be life saving for those with severe allergic reactions to certain substances. The price of this device has been steadily raised by Mylan Pharmaceuticals by more than 500% since 2009, to a list price of US$609 recently. Credible estimates of actual production costs are US$30. Many parents buy these dev
Many readers would have read about the outrageous price hike of the drug Daraprim (pyrimethamine) in the United States, which was acquired in August 2015 by Turing Pharmaceuticals. The price was then promptly raised to US$750 a tablet from US$13.50, bringing the annual cost of treatment for some patients to hundreds of thousands of dollars. This latest drug pricing outrage illustrates the lack of social responsibility among some companies. Another drug, cycloserine, acquired by Rodelis
In the United States, a campaign has been fighting for transparency in the pricing of specialty drugs.